During Tuesday’s Morning trade, Shares of Dynegy Inc. (NYSE:DYN), gained 4.50% to $10.46.
The Public Utilities Commission of Ohio (PUCO) staff has once again supported anti-market subsidies to a large investment grade company, the cost of which will be borne by Ohio residents and businesses in favor of AEP shareholders. PUCO staff recently reached an eight-year agreement with AEP on an above market power purchase agreement (PPA) that guarantees power prices significantly higher than recently’s market prices. This agreement, together with the one with FirstEnergy agreed to on December 1, 2015, will result in higher power costs for the citizens and businesses of Ohio for years to come.
Similar to FirstEnergy, recent publicly-available information reveals that AEP has been awarded more than $1.2 billion in revenues over the next three planning years through the PJM Capacity Auction, with all of the generating plants covered by the PPA agreement receiving awards. This amount is more than $660 million over and above the amount predictable at the time of AEP’s original subsidy request. And, as part of the Capacity Auction results, AEP’s plants are now obligated to run through May 31, 2019 even without the PPAs, meaning the risks of near-term retirements at these facilities are virtually nonexistent.
Dynegy (DYN) co-owns the Conesville, Stuart, and Zimmer Power Stations with AEP, which are comprised in AEP’s PPA agreement with the PUCO. Dynegy, while having an ownership share of these plants will not receive any of the above market revenues from the projected AEP PPAs.
Dynegy Inc., through its auxiliaries, produces and sells electric energy, capacity, and ancillary services in the United States. It operates in three segments, Coal, IPH, and Gas. The company sells its services on a wholesale basis from its power generation facilities.
Shares of BioPharmX Corp (NYSEMKT:BPMX), declined -22.42% to $1.73, during its current trading session.
MomentumStockAlert.com is a newsletter alert service that focuses on companies on the NASDAQ & NYSE. We only highlight quality companies with big potential. This commitment provides our subscribers with only the best recommendations of companies for short and long-term investments. Receive our free trade alerts via text message (SMS) and/or email at http://www.MomentumStockAlert.com. Recently we are focusing on four companies to watch that have been attracting the attention of major investors.
BioPharmX Corporation, a specialty pharmaceutical company, focuses on the development of novel drug delivery products for women’s health, dermatology, and otolaryngology markets. BioPharmX stock traded higher 26% to $2.23 on heavy trading volume, after the pharmaceutical company declared that it might have developed a breakthrough treatment for acne. The company also stated its third quarter financial results after the market closed, showing Net loss for the third quarter was $3.9 million, or $0.18 per share, contrast to a net loss of $2.3 million, or $0.21 per share, during the prior year quarter.
BioPharmX Corporation, a specialty pharmaceutical company, focuses on the development of novel drug delivery products for women’s health, dermatology, and otolaryngology markets. The company offers prescription, over-the-counter (OTC), and supplement products in oral, topical, inhalant, and/or injectable forms. It provides VI2OLET iodine, an OTC dietary supplement molecular iodine tablet that promotes overall breast health and for the alleviation of benign breast pain associated with fibrocystic breast condition.
Finally, Keryx Biopharmaceuticals (NASDAQ:KERX), gained 4.02%, and is now trading at $4.14.
Moments ago, Trader’s Choice released new research updates concerning several important developing situations counting the following equities: TriNet Group Inc (TNET), Xencor Inc (XNCR), Keryx Biopharmaceuticals (KERX) and TeleCommunication Systems, Inc. (TSYS). Trader’s Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
Highlights from recently’s reports comprise:
On Thursday, December 10, 2015, Nasdaq Composite ended at 5,045.17, up 0.44%, Dow Jones Industrial Average advanced 0.47%, to finish the day at 17,574.75, and the S&P 500 closed at 2,052.23, up 0.23%.
- TriNet Group Inc’s stock reduced by 0.10% to close Thursday’s session at USD 19.19. The company’s shares fluctuated in the range of USD 19.12 and USD 19.53. A total of 0.23 million shares exchanged hands, which was lesser than its 50-day daily average volume of 0.52 million shares and was below its 52-week average volume of 0.69 million shares. Over the last three days TriNet Group Inc’s shares have advanced 0.63% while in the past one week it has moved down 1.03%. Furthermore, over the last three months, the stock has gained 13.02% and in the past six months, the shares have shed 33.14%. The company has returned 13.02% in the past three months, on a compounded total return basis. Further, the company is trading at a price to earnings ratio of 56.44. This compares to a historical PE ratio of 140.38.
- Xencor Inc’s stock added 4.19% to close Thursday’s session at USD 14.18. The company’s shares oscillated between USD 13.48 and USD 14.19. The stock recorded a trading volume of 0.31 million shares, which was above its 50-day daily average volume of 0.28 million shares and above its 52-week average volume of 0.25 million shares. Over the last five days, Xencor Inc’s shares have declined by 2.94% while in the past one month, it has gained a momentum of 2.98%. In addition, over the last three months, the stock has lost 16.00% and year to date, the shares have shed 11.60%. The stock has a Price to Sales (ttm) ratio of 47.20 and Price to Book (mrq) ratio of 3.59. The last traded price of the stock is above its 50-Day Moving Average of USD 13.50 and below its 200-Day Moving Average of 17.32.
- Keryx Biopharmaceuticals Inc’s stock advanced 5.11% to close Thursday’s session at USD 4.73. The share price vacillated between USD 4.46 and USD 4.79. The stock recorded a trading volume of 0.92 million shares, which was below its 50-day daily average volume of 2.38 million shares and below its 52-week average volume of 1.89 million shares. Over the last three days Keryx Biopharmaceuticals Inc’s shares have advanced 3.50% and in the past one week it has moved down 9.39%. Moreover, in the last six months, the stock has lost 53.12% and year to date, the shares have shed 66.57%. The stock is at a price to book ratio of 4.04. The historical PB ratio is near to 17.85. Additionally, the stock is trading at a price to sales ratio of 57.78. The last traded price of the stock is below its 50-Day Moving Average of USD 5.01 and below its 200-Day Moving Average of 6.61.
Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on providing therapies for patients with renal disease in the United States. Its lead product Auryxia (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes, in addition to treats iron deficiency anemia.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.